BoB, Sun Pharma, Tech Mahindra Q4 results today; What to watch

Sharekhan pencilled in 17.80 per cent rise in net profit on 18.40 per cent growth in net interest income in the March quarter.

ThinkStock Photos
ICICIdirect.com sees 7.30 per cent sequential drop in net profit of Tech Mahindra.
Bank of Baroda, Sun Pharma and Tech Mahindra tracked higher ahead of their financial results for the March quarter later in the day.

This is what top brokerage houses have to say.

Bank of Baroda: Prabhudas Lilladher believes that Bank of Baroda may report 11.20 per cent year-on-year fall in net profit in Q4 FY18. Net interest income and pre-provisioning operating profit (PPOP) are likely to rise by 15.80 per cent and 5.60 per cent, respectively.


“Operating performance would remain better than most PSU peers on better loan growth of 10 per cent and improved NIM levels. We factor in much higher slippages of Rs 7,850 crore against over Rs 5,000 crore in Q3 FY18. But the bank is likely to maintain PCR at 57-59 per cent,” the brokerage firm said in a report.

Sharekhan pencilled in 17.80 per cent rise in net profit on 18.40 per cent growth in net interest income in the March quarter.

Sun Pharma: Sharekhan predicts 42.80 per cent annual drop in net profit of Sun Pharma in Q4 FY18. The brokerage house also sees 10 per cent and 102.10 bps drop in net sales and operating profit margin for January-March.
ADVERTISEMENT

According to ICICIdirect.com, revenue of Sun Pharma is likely to decline 6 per cent yoy, mainly due to 19 per cent likely fall in the US and price erosion across portfolio. Taro's sales are expected to come down by 25 per cent. EBITDA margin is seen to drop by 74 basis points to 20.9 per cent and net profit is expected to decline 26 per cent due to subdued operational performance and higher tax outgo.

Tech Mahindra: ICICIdirect.com is expecting 48.60 per cent yoy rise in net profit for Tech Mahindra at Rs 874.50 crore for the three months to March. It has further projected growth of 2.50 per cent and 5.30 per cent in revenue and EBITDA, respectively.

The brokerage house expects US dollar revenues to grow 2.5 per cent quarter on quarter to $1,239 million led by enterprise business and Comviva seasonality. Rupee revenues may jump 2.5 per cent to Rs 7,973.4 crore. EBITDA margins could expand 40 bps to 16.7 per cent on revenue growth aided by cross currency tailwinds.

ICICIdirect.com sees 7.30 per cent sequential drop in net profit of Tech Mahindra.
ADVERTISEMENT
ADVERTISEMENT
READ MORE

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Text Size:AAA
Success
This article has been saved

*

+